Apoptosis markers and progression of glaucomatous optic neuropathy after surgical treatment of primary open-angle glaucoma


  • S.Yu. Mogilevskyy Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • A.V. Serdyuk Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine
  • S.V. Ziablitsev Bogomolets National Medical University, Kyiv, Ukraine




primary open-angle glaucoma, glaucomatous optic neuropathy, surgical treatment, tumor necrosis factor α, Fas-ligand, sFas/APO-1


Background. The mechanisms of apoptosis of optic nerve neurons in primary open-angle glaucoma (POAG) continue to be studied. It was found that markers of this process are tumor necrosis factor α (TNFα), Fas-ligand (FasL) and soluble form of Fas-receptor (sFas/APO-1). The purpose of the study was to investigate the relationship of apoptosis markers (TNFα, FasL and sFas/APO-1) with the progression of glaucomatous optic neuropathy after surgical treatment for primary open-angle glaucoma. Materials and methods. Sixty-nine patients (69 eyes) with POAG stages I–III were examined, they underwent trabeculectomy with Ex-Press shunt implantation. The content of specified markers in the intraocular fluid was determined by enzyme-liked immunoassay. Repeated ophthalmologic examination was performed in 3 and 6 months and after one year. The control group consisted of 25 patients (25 eyes) who underwent surgery for age-related cataracts. The content of apoptosis markers in the intrao­cular fluid was also studied in these patients. Statistical analysis was performed using the software packages SPSS 11.0, MedStat. Results. The intraocular pressure did not differ 3 months after surgery in the presence or absence of postoperative progression of optic neuropathy. The content of TNFα was highest in POAG stage III and exceeded that of in the control group by 2.3 times (p < 0.001). Similar differences are noted for the FasL content, which was maximal in stage III and 1.9-fold higher than in controls (p < 0.001). The level of sFas/APO-1 according to POAG stage was lower (p < 0.001). The content of TNFα and FasL in the intraocular fluid was higher with the progression of optic neuropathy, while the level of sFas/APO-1 was lower (p < 0.001). The maximum absolute difference is observed for sFas/APO-1 (2.5 times), it was smaller for TNFα (1.7 times) and FasL (1.6 times). Conclusions. Comparison of the obtained data with literature indicates an important pathogenic role of apoptosis markers and may indicate the possibility of their use to predict the development and progression of glaucomatous optic neuropathy in POAG and after its surgical treatment.


Nesterov AP. [Glaucoma. 2nd. Ed.]. Medical News Agency: Russia, 2014. 360 p. Russian.

EGS Guidelines 4th Ed. European Glaucoma Society. Available on: https://www.eugs.org/eng/egs_guidelines_reg.asp?l=1.

Mogilevskyy SIu, Ziablitsev SV, Denisiuk LI. Primary open-angle glaucoma progression depending on clinical indices at presentation. J.ophthalmol. (Ukraine). 2017;1:15-19. doi: https://doi.org/10.31288/ oftalmolzh201711519.

US Eye disease statistics. American academy of ophthalmology. Available at: https://www.aao.org/eye-disease-statistics.

Vitovska OP. Organizational and resource support for the implementation of the National Strategy for Combating Primary Glaucoma in Ukraine. Ukraine. The health of the nation. 2010;1(13):40-7.

Tham YC, Li X., Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013.

Youngblood H, Hauser MA, Liu Y. Update on the genetics of primary open-angle glaucoma. Exp Eye Res. 2019 Sep 13;188:107795. doi: 10.1016/j.exer.2019.107795.

Rusciano D, Pezzino S, Mutolo MG, Giannotti R, Librando A, Pescosolido N. Neuroprotection in glaucoma: old and new promising treatments. Adv Pharmacol Sci. 2017;2017:4320408. doi: 10.1155/2017/4320408.

Mudassar Imran Bukhari S, Yew KK, Thambiraja R, Sulong S, Ghulam Rasool AH, Ahmad Tajudin LS. Microvascular endothelial function and primary open angle glaucoma. Ther Adv Ophthalmol. 2019 Aug 22;11:2515841419868100. doi: 10.1177/2515841419868100.

Mikheytseva IN. [Glaucoma optic neuropathy - the main aspects of pathogenesis]. Archive clin and experiment med. 2009; 18(2):235-40. Russian.

"Apoptosis – an overview". ScienceDirect Topics. Retrieved 2019-03-19. Available at: https://www.sciencedirect.com.

Chen Q, Xi X, Zeng Y, He Z, Zhao J, Li Y. Acteoside inhibits autophagic apoptosis of retinal ganglion cells to rescue glaucoma-induced optic atrophy. J Cell Biochem. 2019 Aug;120(8):13133-13140. doi: 10.1002/jcb.28586.

Levkovitch-Verbin H. Retinal ganglion cell apoptotic pathway in glaucoma: Initiating and downstream mechanisms. Prog Brain Res. 2015;220:37-57. doi: 10.1016/bs.pbr.2015.05.005.

Serdyuk VM. [Clinical and experimental substantiation of neuroprotection in the complex of treatment of patients with primary open-angle glaucoma]. Manuscript. Doctor of Science. National Academy of Sciences of Ukraine. Odessa. 14.01.18 – ophthalmology. - 2015. - 35 p. Ukrainian.

Slepova OS, Frolov MA, Morozov NS, Frolov AM, Lovpache JN. [Markers of Fas-mediated apoptosis in primary open-angle glaucoma and opportunities of their pharmacological correction]. Vestnik Oftalmologii. 2012; 4:27-31. Russian.

Misyurin VA. [The structure and properties of the main receptors and ligands of the external apoptosis pathway]. Rus biotherapevt journal. 2015;14 (2): 23-30. Russian.

Kurysheva NI. [Glaucoma optic neuropathy (literature review)]. Moscow: MEDpress-inform, 2006. 136 p. Russian.

Sun Y, Zhang B, Zhou R, Wang T, Deng J. Trabeculectomy and EX-PRESS implantation in open-angle glaucoma: An updated meta-analysis of randomized controlled trials. J Ophthalmol. 2019 Sep 24; 2019:2071506. doi: 10.1155/2019/2071506.

Mogilevskyy SIu, Serdyuk OV. [Progression of glaucomatous optic neuropathy after different anti-glaucomatous operations]. Visnik problem biologii I medicini. 2019;4(2):195-9. doi: 10.29254/2077-4214-2019-4-2-154-195-199. Ukrainian

Petrov SJ, Fokina ND, Sherstneva LV, Vostrukhin SV, Safonova DM. [Etiology of primary glaucoma: modern theories and researches]. Ophthalmol statements. 2015; 8(2):47-56. Russian.

Beletskaya IS, Astakhov SYu. [The role of matrix metalloproteinases in the pathogenesis of glacoma]. Ophthalmol statements. 2015;8(3):28-43. Russian.

Sokolov VA, Levanova OH. [The role of matrix metalloproteinases in the pathogenesis of primary open-angle glaucoma]. Rus Med Biol Bul named after academician I.P. Pavlov. 2013(2):136-41.

Williams PA, Marsh-Armstrong N, Howell GR. Neuroinflammation in Glaucoma: A New Opportunity. Exp Eye Res. 2017 Apr;157:20-27. doi: 10.1016/j.exer.2017.02.014.

He S, Stankowska DL, Ellis DZ, Krishnamoorthy RR, Yorio T. Targets of Neuroprotection in Glaucoma. J Ocul Pharmacol Ther. 2018;34(1-2):85‐106. doi:10.1089/jop.2017.0041.

Pinazo-Durán MD, Zanón-Moreno V, García-Medina JJ, Gallego-Pinazo R. Evaluation of presumptive biomarkers of oxidative stress, immune response and apoptosis in primary open-angle glaucoma. Curr Opin Pharmacol. 2013;13(1):98‐107. doi:10.1016/j.coph.2012.10.007

Razeghinejad MR, Kamali-Sarvestani E. Aqueous humor levels of soluble Fas and Fas-ligand in patients with primary open angle and pseudoexfoliation glaucoma. Iran J Immunol. 2007;4(4):215‐219.





Clinical Ophthalmology